Factors of risk ateroscleróticos in mature patients with leukemia sharp mieloide
Keywords:
leukemia sharp mieloide, aterosclerosis, factors of risk.Abstract
Introduction:
The leukemia sharp mieloide, constitutes the variety of more common leukemia in the adult. The aterosclerosis is a gradual process that arises from the birth and he/she goes progressing in successive decades of the life, until the appearance of clinical manifestations, illnesses multifactoriales or complex. Objective: To carry out a revision of the factors of risk ateroscleróticos related with the adult's leukemia sharp mieloide. Methods: He/she was carried out a revision of the literature in the databases of Pubmed, Scielo, Science Direct and the motor of search of Academic google, they took like references the articles published in the last 5 years. Results: The leukemia sharp mieloide represents 80% of the total of the adult's sharp leukemias and he/she has been proven that they constitute people's of the third age illnesses. Factors of risk that define presage in this entity exist. The aterosclerosis is an illness inflammatory progressive chronicle with high participation inmunitaria. The factor of good known and studied risk is the obesity, although other classic denominated factors of risk exist; important in the development of cardiovascular illnesses and cerebrovasculares; also ddel lifestyle and the psychological estrés. However, they seem to coexist other clinical situations and associate inflammatory markers or not to the classic factors that represent factors of risk aterogénicos. Conclusions: The factors of risk ateroscleróticos, as the age, the obesity, disfunción endotelial, systemic inflammation, hipertrigliceridemia, the metabolic syndrome, the factors homeostáticos, profile lipídico, the infections and the inflammation have influence in the complications of the patients with leukemia sharp mieloide.
Downloads
References
1. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American
Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid
leukemia in older adults. Blood Adv. 2020 [acceso 08/09/2021];4 (15):3528-49.
Disponible en: http://www.ioncol.com/upfile/down/202008281309.pdf
2. Mehranfar S, Zeinali S, Hosseini R, Mohammadian M, Akbarzadeh A, Feizi AHP.
History of leukemia: diagnosis and treatment from beginning to now. Galen Med J.
2017 [acceso
08/09/2021];6(1):12-22. Disponible en:
http://gmj.ir/index.php/gmj/article/view/702.
3. Cuba. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas
de Salud. Anuario Estadístico de Salud 2023. [acceso 08/09/2021]. Disponible en:
http://files.sld.cu/bvscuba/files/2020/05/AnuarioElectr%C3%B3nicoEspa%C3%B1ol-
2021-ed-2022.pdf.
4. Groarke EM. Clin Geriatric Med. 2019 [acceso 23/04/2025];35(3):285-93.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/31230730/
5. American Cancer Society. Cancer Facts Figures 2021. Atlanta, GA: American
Cancer Society. 2021 [acceso 23/04/2025]. Disponible en:
6. American Cancer Society. Estadísticas importantes sobre la leucemia mieloide
aguda (AML).
2024 [acceso
20/05/2025]. Disponible en:
https://www.cancer.org/content/dam/CRC/PDF/Public/9064.00.pdf
7. Sekeres MA, Gordon G, Gregory A. American Society of Hematology 2020
guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Blood Adv. 2020 [acceso 23/04/2025];4:3528. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/32761235/
8. Martínez-Acosta G, Rubio-Anguiano BL, López-Salvio YM. Aspectos geriátricos en
las neoplasias hematológicas. El Residente. 2017 [acceso 23/04/2025];12(1):4-17.
Disponible en: https://www.medigraphic.com/pdfs/residente/rr-2017/rr171b.pdf
9. Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American
Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid
leukemia in older adults. Blood Adv. 2020 [acceso 09/09/2021];4(15):3528-49.
Disponible en:
http://www.ioncol.com/upfile/down/202008281309.pdf
10. Díaz-Perera CA, Fernández G, Pérez EA. Papel de la epigenética en la
aterosclerosis y sus enfermedades consecuentes. Rev Cuban Salud Pública. 2022
[acceso 23/04/2025];48(Supl):e2673:15. Disponible en:
file:///D:/Users/bioestad.HHA/Downloads/admin,+a0_2673.pdf. 11. Raposeiras RS, Cordero A. La relación bidireccional entre el cáncer y la
ateroesclerosis.
Rev Esp Cardiol.
2019;72(6):487-92. DOI:
https://doi.org/10.1016/j.recesp.2018.12.011
12. Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene
mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020 [acceso
23/04/2025];9(4):1-11. DOI: https://doi.org/10.1186/s40164-020-00161-7
13. Amacherla K, Well JA 4th, Bick AG. Clonal hematopoiesis and vascular disease.
Semin Immunopathol. 2022 [acceso 23/04/2025];44(3):303-08. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/35122117/
14. Liesveld JL, Lichtman MA. Acute myelogenous leukemia. In: Williams'
Hematology. 10th ed. New York: McGraw-Hill; 2021. 2845-3017. [acceso
23/04/2025]. Disponible en:
https://accessmedicine.mhmedical.com/content.aspx?bookid=2962§ionid=252
532651
15. Hoffman R, Benz EJ, Silberstein LE. Hematology Basic Principles and Practice.
ELSEVIER. 20217. DOI: https://doi.org/10.1016/C2013-0-23355-9
16. Intó X, Fanlo M, Esteve V, Millán J; Grupo de Trabajo Dislipemia Aterogénica.
Sociedad Española de Arteriosclerosis (SEA). Remnant cholesterol, vascular risk, and
prevention of atherosclerosis. Clin Investig Arterioscler. 2023;35(4):206-17.
DOI: https://doi.org/10.1016/j.arteri.2023.02.001
17. Belli C, Correa W, González J, Ferrari L, Dick H, Cranco S, et al. Influencia de los
hallazgos citogenéticos y moleculares en el pronóstico y respuesta a tratamiento de
pacientes con leucemia mieloide aguda. Rev Hematol. 2020 [acceso
23/04/2025];24(1):9-20. Disponible en:
http://revistahematologia.com.ar/index.php/Revista/article/view/267.
18. American Cancer Society. Cancer Facts Figures 2021. Atlanta, GA: American
Cancer Society; 2021 [acceso 23/04/2025]. Disponible en:
19. Sasaki S, Higashi Y, Nakagawa K, Kimura M, Noma K, Sasaki S, et al.
A low-calorie diet improves endothelium-dependent vasodilation in obese patients
with essential hypertension. American Journals Hypertensive. 2002;15(4 Pt 1):302-9.
DOI: https://doi.org/10.1016/s0895-7061(01)02322-6
20. Koskinas KC, Van Craenenbroeck EM, Antoniades C. Obesity and cardiovascular
disease: an ESC clinical consensus statement. European Heart Journal.
2024;45(38):4063-8. DOI: https://doi.org/10.1093/eurheartj/ehae508
21. Bu LL, Yuan HH, Xie LL, Guo MH, Liao DF, Zheng XL. New Dawn for
Atherosclerosis: Vascular Endothelial Cell Senescence and Death. Int J Mol Sci.
2023;24(20):15160. DOI: https://doi.org/10.3390/ijms242015160.
22. Song M, Wang H, Ye Q. Increased circulating vascular endothelial growth factor in
acute myeloid leukemia patients: a systematic review and meta-analysis. Syst Rev.
2020;9(1):103. DOI: https://doi.org/10.1186/s13643-020-01368-9. 23. Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and
atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct
Target Ther. 2022;7(1):131. DOI: https://doi.org/10.1038/s41392-022-00955-7
24. Liu F, Wang Y, Yu J. Role of inflammation and immune response in
atherosclerosis: Mechanisms, modulations, and therapeutic targets. Human
Immunology.
2023;84(9):439-49. DOI:
https://doi.org/10.1016/j.humimm.2023.06.002
25. Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ. et al. An inflammatory
state remodels the immune microenvironment and improves risk stratification in
acute myeloid leukemia. Nat Cancer. 2023 [acceso 23/04/2025];4(1):27-42.
Disponible en: https://www.nature.com/articles/s43018-022-00480-0#citeas
26. Custodio-Chablè SJ, Lezama RA, Reyes-Maldonado E. Platelet activation as a
trigger factor for inflammation and atherosclerosis. Cir Cir. 2020;88(2):233-43. DOI:
https://doi.org/10.24875/CIRU.19000725
27. Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau's
syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204-8. DOI:
https://doi.org/10.1093/jjco/hyv165
28. Olivi M, Di Biase F, Lanzarone G, Arrigo G, Martella F, Apolito V. et al. Thrombosis
in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges.
Curr Treat Options Oncol. 2023 [acceso 23/04/2025];24(6):693-710. Disponible en:
https://link.springer.com/article/10.1007/s11864-023-01089-w
29. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and
thrombosis in acute leukemia: what does the future of therapy look like? Thromb
Res. 2007;120(Suppl)2:S99-106.
DOI:
https://doi.org/10.1016/S0049-
3848(07)70137-8
30. López A, Rendón S, Barreto EE, Álvarez N, Acosta M. Índice predictivo para la
estratificación del riesgo de enfermedad tromboembólica venosa en pacientes con
hemopatías malignas. Acta Médica del Centro. 2021 [acceso 23/04/2025];15(4).
Disponible en:
https://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S2709-
79272021000400511&Ing=pt&nrm=iso&tlng=es
31. Li B, Xia Y, Hu B. Infection and atherosclerosis: TLR-dependent pathways. Cell
Mol Life Sci. 2020;77(14):2751-69. DOI: https://doi.org/10.1007/s00018-020-03453-7
32. Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The Gut Microbiota and
Inflammation: An Overview. Int J Environ Res Public Health. 2020;17(20):7618. DOI:
https://doi.org/10.3390/ijerph17207618
33. Gurfinkel EP. Infección y aterosclerosis. Rev Cuban Med. 2001 [acceso
23/04/2025];40(4):273-87. Disponible en:
http://scielo.sld.cu/pdf/med/v40n4/med06401.pdf
34. Lusta KA, Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Orekhov AN.
Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of
Atherosclerosis Development Have a Substruction? Cells. 2023;12(5):707. DOI:https://doi.org/10.3390/cells12050707 35. Wieczorek E, Ćwiklińska A, Jankowski M. Hypertriglyceridemia, a causal risk
factor for atherosclerosis, and its laboratory assessment. Clin Chem Lab Med.
2022;60(8):1145-59. DOI: https://doi.org/10.1515/cclm-2022-0189
36. Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, et al. The Role
of Lipids and Lipoproteins in Atherosclerosis. 2019 [acceso 23/04/2025]. Disponible
en: https://www.ncbi.nlm.nih.gov/books/NBK343489/
37. Rodríguez-Morales FM. Perfil lipídico en el diagnóstico de pacientes con
arteriosclerosis en América Latina. Journal Scientific MQ RInvestigar.
2024;8(1):2329-46. DOI: https://doi.org/10.56048/MQR20225.8.1.2024.2329-2346
38. Herrera González A, Peña Garcel Y, Soto Matos J, León Patiño EH. Utilidad de los
índices aterogénicos del perfil lipídico en el diagnóstico de aterosclerosis subclínica.
Rev Cuban Med. 2022 [acceso 15/11/2026];61(3):e2691. Disponible en:
https://revmedicina.sad.cu/index.php/med/article/view/2691
39. Finch ER, Smith SA, Yang W, Liu Y, Kornegay NM, Panetta JC, et al. Asparaginase
formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic
leukemia.
Pediatr Blood Cancer. 2020;67(1):e28040.
DOI:
https://doi.org/10.1002/pbc.28040.
40. Sanoval R, Gupta V. Hyperlipidemia in a case of acute lymphoblastic leukemia.
India J Cancer. 2019;56(2):180-1. DOI: https://doi.org/10.4103/ijc.IJC-724-18
41. Esfandbod M, Abazaria Tehrani M, Haghshomar M, Arya P, Shateri Amiri B,
Toogeh G, Keyhani M. Association between Perceived Stress and Neutropenia in
Patients with Leukemia under Chemotherapy. Int J Hematol Oncol Stem Cell Res.
2022;16(2):103-9. DOI: https://doi.org/10.18502/ijhoscr.v16i2.9203
42. Arrobas T, Guijarro C, Campuzano R, Rodríguez M, Valderrama JF, Perez A, et al.
Documento de Consenso para la determinación e informe del perfil lípido en
laboratorios clínicos españoles. Clin Investig Arterioscler. 2023;35(2):91-100. DOI:
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Yusaima Rodríguez Fraga, Servando Roig Verdecia, Mildrey Gutiérrez Izquierdo

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.

